Related Experiment Video

Updated: Jul 8, 2026

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis

Andrea Zambruni1, Franco Trevisani, Antonio Di Micoli

  • 1Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Semeiotica Medica, Alma Mater Studiorum, Università di Bologna, Bologna, Italy. azambruni@hotmail.com

Journal of Hepatology
|January 16, 2008
PubMed

Insights

Chronic beta-blockade with nadolol effectively shortens the QT interval in cirrhotic patients with baseline prolongation. This effect appears independent of changes in hepatic vein pressure gradient.

Area of Science:

  • Cardiology
  • Hepatology
  • Pharmacology

Background:

  • QT interval prolongation is a common complication in cirrhosis, associated with poor prognosis and increased risk of ventricular arrhythmias.
  • The impact of interventions like beta-blockade on QT interval in cirrhosis requires further investigation.

Purpose of the Study:

  • To evaluate the effect of chronic beta-blockade, specifically nadolol, on QT interval prolongation in patients with cirrhosis.

Main Methods:

  • Thirty cirrhotic patients underwent clinical evaluation, ECG, and hepatic vein pressure gradient (HVPG) measurements before and after prophylactic nadolol administration.
  • QT interval was corrected using the cirrhosis-specific formula and other standard formulas.
  • Changes in QT interval and HVPG were analyzed in relation to baseline values and treatment.

Main Results:

  • QT interval prolongation (QTcirrhosis) was observed in 33% of patients and correlated with the Child-Pugh score.
  • Nadolol significantly shortened the QT interval only in patients with baseline prolongation, with no significant change in those with normal baseline values.
  • A decrease in HVPG was noted post-nadolol, but changes in HVPG did not correlate with QT interval modifications.

Conclusions:

  • Chronic beta-blockade with nadolol shortens the QT interval in cirrhotic patients, but this effect is primarily observed in those with pre-existing QT prolongation.
  • The observed QT shortening is likely a direct cardiac effect of nadolol, independent of its impact on portal hypertension.
Abstract

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...